MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145027 | Name: CP-55940 H-3

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CP-55940 H-3 is a biochemical.

Chemical Structure

CP-55940 H-3
CP-55940 H-3
CAS#1095586-82-5

Theoretical Analysis

MedKoo Cat#: 145027

Name: CP-55940 H-3

CAS#: 1095586-82-5

Chemical Formula: C24H38T2O3

Exact Mass: 380.3142

Molecular Weight: 380.60

Elemental Analysis: C, 75.74; H, 11.65; O, 12.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CP-55940 H-3; CP55940 H-3; [3H]CP-55940; CP 55940 H-3;
IUPAC/Chemical Name
2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl-3,4-t2)phenol
InChi Key
YNZFFALZMRAPHQ-BVJNDEIJSA-N
InChi Code
1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3/t18-,20-,22-/m1/s1/i7T,14T/t7?,14?,18-,20-,22-
SMILES Code
[3H]C(CCCC)C([3H])C(C)(C)C1=CC(O)=C(C=C1)[C@@H]2C[C@H](O)CC[C@H]2CCCO
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 380.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sundram S, Copolov D, Dean B. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol. 2005 May;371(5):428-33. doi: 10.1007/s00210-005-1074-2. Epub 2005 Jul 2. PMID: 15995876. 2: Norwood CS, Cornish JL, Mallet PE, McGregor IS. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol. 2003 Mar 28;465(1-2):105-14. doi: 10.1016/s0014-2999(03)01455-9. PMID: 12650839. 3: Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 2001;103(1):9-15. doi: 10.1016/s0306-4522(00)00552-2. PMID: 11311783. 4: Fischer BD, Ward SJ, Henry FE, Dykstra LA. Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects. Neuropharmacology. 2010 Feb;58(2):544-50. doi: 10.1016/j.neuropharm.2009.08.005. Epub 2009 Aug 21. PMID: 19699755; PMCID: PMC2813317. 5: Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol. 2005 Sep;16(5-6):381-8. doi: 10.1097/00008877-200509000-00010. PMID: 16148442. 6: Avdesh A, Hoe Y, Martins RN, Martin-Iverson MT. Pharmacological effects of cannabinoids on the reference and working memory functions in mice. Psychopharmacology (Berl). 2013 Jan;225(2):483-94. doi: 10.1007/s00213-012-2834-6. Epub 2012 Aug 19. PMID: 22903389. 7: Tomiyama KI, Funada M. Synthetic cannabinoid CP-55,940 induces apoptosis in a human skeletal muscle model via regulation of CB1 receptors and L-type Ca2+ channels. Arch Toxicol. 2021 Feb;95(2):617-630. doi: 10.1007/s00204-020-02944-7. Epub 2020 Nov 10. PMID: 33174160. 8: Wiley JL, Matthew Walentiny D, Vann RE, Baskfield CY. Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle. Behav Pharmacol. 2011 Sep;22(5-6):480-8. doi: 10.1097/FBP.0b013e328348eced. PMID: 21712709; PMCID: PMC3155614. 9: Hengst JA, Nduwumwami AJ, Raup-Konsavage WM, Vrana KE, Yun JK. Inhibition of Sphingosine Kinase Activity Enhances Immunogenic Cell Surface Exposure of Calreticulin Induced by the Synthetic Cannabinoid 5-epi-CP-55,940. Cannabis Cannabinoid Res. 2022 Oct;7(5):637-647. doi: 10.1089/can.2021.0100. Epub 2021 Nov 26. PMID: 34846947; PMCID: PMC9587795. 10: Gilbert MT, Sulik KK, Fish EW, Baker LK, Dehart DB, Parnell SE. Dose- dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice. Neurotoxicol Teratol. 2016 Nov-Dec;58:15-22. doi: 10.1016/j.ntt.2015.12.004. Epub 2015 Dec 18. PMID: 26708672; PMCID: PMC4912947. 11: Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2):129-80. doi: 10.1016/s0163-7258(97)82001-3. PMID: 9336020. 12: Johnston JR, Freeman KG, Edwards GL. Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin. Physiol Rep. 2018 Dec;6(23):e13927. doi: 10.14814/phy2.13927. PMID: 30512249; PMCID: PMC6278814. 13: Yang L, Zhu X, Finlay DB, Green H, Glass M, Duffull SB. A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid (CB1 ) receptor. Br J Pharmacol. 2023 Oct;180(20):2661-2676. doi: 10.1111/bph.16158. Epub 2023 Jul 2. PMID: 37277184. 14: Coronado-Álvarez A, Romero-Cordero K, Macías-Triana L, Tatum-Kuri A, Vera- Barrón A, Budde H, Machado S, Yamamoto T, Imperatori C, Murillo-Rodríguez E. The synthetic CB1 cannabinoid receptor selective agonists: Putative medical uses and their legalization. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110:110301. doi: 10.1016/j.pnpbp.2021.110301. Epub 2021 Mar 17. PMID: 33741446. 15: Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 1995 Jun;34(6):669-76. doi: 10.1016/0028-3908(95)00027-4. PMID: 7566504. 16: Thayer A, Murataeva N, Delcroix V, Wager-Miller J, Makarenkova HP, Straiker A. THC Regulates Tearing via Cannabinoid CB1 Receptors. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):48. doi: 10.1167/iovs.61.10.48. PMID: 32852544; PMCID: PMC7452851. 17: Lamanna-Rama N, MacDowell KS, López G, Leza JC, Desco M, Ambrosio E, Soto- Montenegro ML. Neuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence. Eur Neuropsychopharmacol. 2023 Apr;69:60-76. doi: 10.1016/j.euroneuro.2023.01.005. Epub 2023 Feb 11. PMID: 36780817. 18: McGregor IS, Issakidis CN, Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav. 1996 Mar;53(3):657-64. doi: 10.1016/0091-3057(95)02066-7. PMID: 8866969. 19: Tersigni TJ, Rosenberg HC. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res. 1996 Sep 16;733(2):184-92. doi: 10.1016/0006-8993(96)00533-1. PMID: 8891301. 20: Viveros MP, Llorente R, Moreno E, Marco EM. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav Pharmacol. 2005 Sep;16(5-6):353-62. doi: 10.1097/00008877-200509000-00007. PMID: 16148439.